THWM
SUPN icon

Taylor Hoffman Wealth Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Taylor Hoffman Wealth Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-285
Closed -$7K – 326
2020
Q2 		$7K Sell
285
-38,033
-99% -$840K ﹤0.01% 313
2020
Q1 		$689K Buy
38,318
+33,793
+747% +$710K 0.66% 59
2019
Q4 		$107K Buy
+4,525
New +$110K 0.07% 156

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Taylor Hoffman Wealth Management's SUPN Position: Q3 2020 in Review

Taylor Hoffman Wealth Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2020, closing a stake of 285 shares — an estimated $7K sold.

Taylor Hoffman Wealth Management first reported a position in SUPN in Q4 2019 and held it in 3 quarters. The position peaked at $689K in Q1 2020. 209 funds tracked by Wall St. Rank hold SUPN as of Q3 2020.

  • Taylor Hoffman Wealth Management reported no remaining Supernus Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Taylor Hoffman Wealth Management sold 285 Supernus Pharmaceuticals shares in Q3 2020, an estimated $7K.
  • Taylor Hoffman Wealth Management first reported a position in Supernus Pharmaceuticals in Q4 2019 and held it in 3 quarters.
  • Taylor Hoffman Wealth Management's Supernus Pharmaceuticals position peaked at $689K in Q1 2020.
  • 209 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2020.

Based on Taylor Hoffman Wealth Management's 13F filing for Q3 2020, filed 29 Oct 2020.